You are here

Material in Dissolvable Sutures Could Treat Brain Infections, Reducing Hospital Stays

Researchers test fibers that release vancomycin (August 7)

A plastic material already used in absorbable surgical sutures and other medical devices shows promise for continuous administration of antibiotics to patients with brain infections, scientists are reporting in a new study. Use of the material, placed directly on the brain’s surface, could reduce the need for weeks of costly hospital stays now required for such treatment, they say in the journal ACS Chemical Neuroscience.

Dr. Shih-Jung Liu and colleagues explain that infections are life-threatening complications that occur in about 5 to 10 percent of patients who have brain surgery. Current treatment involves intravenous antibiotics for up to 8 weeks and extended, costly hospital stays. Previous studies showed that drug-delivering plastics could release antibiotics directly into the brain. However, additional surgery was needed to remove the plastic when treatment was finished. Liu’s team sought to develop a biodegradable version using a dissolvable plastic called PLGA.

They describe development of PLGA fibers that release vancomycin, a powerful antibiotic that kills many microbes, including methicillin-resistant Staphylococcus aureus (MRSA), which shrugs off most other known antibiotics. They tested the fibers in rats, which are stand-ins for humans in these types of studies. The fibers successfully released vancomycin for more than 8 weeks in the brain and did so without apparent adverse effects.

Source: EurekAlert; August 7, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs